| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
RESEARCH |
1 Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, H-6720 Szeged, Eötvös u. 6, Hungary, 2 Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, H-6726 Szeged, Temesvári krt. 62, Hungary and 3 Department of Obstetrics and Gynecology, Faculty of Medicine, University of Szeged, WHO Collaborating Research Center in Human Reproduction, H-6725 Szeged, Semmelweis u. 1, Hungary
Correspondence should be addressed to George Falkay; Email: falkay{at}pharma.szote.u-szeged.hu
The effectiveness of ß2-agonists in preterm delivery is reduced by several factors. The aim of this study was to determine the influence of late pregnancy in the uterus-relaxing effect of terbutaline in the rat in vitro.
Rat uterine tissues from late pregnancy (days 15, 18, 20 and 22) were used. In vitro electrical field-stimulation (EFS) was used to evoke contractions. The radioligand-binding technique, reverse transcription-polymerase chain reaction and radioimmunoassay technique were used to determine the ß-adrenergic receptor density and mRNA level and the plasma sex hormone level, respectively. The activated G-protein level of the ß-adrenergic receptors was investigated by a radiolabelled GTP binding assay.
EFS-induced contractions were inhibited by terbutaline. This effect decreased towards term with respect to both the EC50 and maximal inhibition values. A drop in plasma progesterone level was also detected. Binding studies revealed an increase in ß-adrenergic receptor number on the last day of pregnancy, which correlated with the change in receptor mRNA level. The G-protein-activating effect of terbutaline decreased continuously between days 15 and 20. Surprisingly, terbutaline decreased the G-protein activation to below the basal level on day 22. However, progesterone pretreatment set back the uterine action of terbutaline, increased the density of the ß2-adrenergic receptors and their mRNA level and increased the G-protein-activating property of terbutaline.
These data provide evidence of a pregnancy-induced decrease in activated G-protein level after ß2-agonist stimulation. The decrease in plasma progesterone level has a crucial role in this process. The effects of ß2-adrenergic receptor agonists in tocolytic therapy may possibly be potentiated with progesterone.
This article has been cited by other articles:
![]() |
L. Anderson, W. Martin, C. Higgins, S. M. Nelson, and J. E. Norman The Effect of Progesterone on Myometrial Contractility, Potassium Channels, and Tocolytic Efficacy Reproductive Sciences, November 1, 2009; 16(11): 1052 - 1061. [Abstract] [PDF] |
||||
![]() |
R. Minorics, R. Gaspar, A. Gal, A. Klukovits, and G. Falkay Progesterone decreases the relaxing effect of the {beta}3-adrenergic receptor agonist BRL 37344 in the pregnant rat myometrium Reproduction, August 1, 2009; 138(2): 383 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Carvajal, A. M. Delpiano, M. A. Cuello, J. A. Poblete, P. C. Casanello, L. A. Sobrevia, and C. P. Weiner Brain Natriuretic Peptide (BNP) Produced by the Human Chorioamnion May Mediate Pregnancy Myometrial Quiescence Reproductive Sciences, January 1, 2009; 16(1): 32 - 42. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |